STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Not yet recruiting
- Solid Tumor
- Solid Tumor, Adult
- Sargramostim
- Ipilimumab-containing therapy
- (no location specified)
2022-03-09
Mar 9, 2022D
Recruiting
- Unresectable Melanoma
- +3 more
- Sargramostim (GM-CSF)
- Pembrolizumab (anti-PD-1)
- Boston, Massachusetts
- +1 more
2021-09-15
Sep 15, 2021N
Completed
- COVID-19
- Sargramostim
- Placebo
- Narita City, Chiba, Japan
- +6 more
2021-11-01
Nov 1, 2021C
Completed
- Autoimmune Pulmonary Alveolar Proteinosis
- Sargramostim
- Los Altos, California
- +1 more
2021-08-02
Aug 2, 2021U
Completed
- Diffuse, Large B-Cell, Lymphoma
- Los Angeles, CaliforniaUSC Norris Comprehensive Cancer Center
2021-11-15
Nov 15, 2021S
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Azacitidine
- Sargramostim
- Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021-08-06
Aug 6, 2021U
Completed
- COVID-19
- Sargramostim
- Control
- Brugge, Belgium
- +3 more
2021-03-01
Mar 1, 2021P
Completed
- COVID-19
- SARS-CoV-2
- Sargramostim
- Standard of care
- Fullerton, California
- +10 more
2022-02-16
Feb 16, 2022N
Recruiting
- Transplant-Related Hematologic Malignancy
- Sargramostim
- Control Arm
- Atlanta, GeorgiaNorthside Hospital
2022-04-04
Apr 4, 2022N
Active, not recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +4 more
- Falimarev
- +3 more
- New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
2022-01-04
Jan 4, 2022M
Active, not recruiting
- Childhood Astrocytoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
- Rochester, MinnesotaMayo Clinic
2021-08-17
Aug 17, 2021U
Completed
- Recurrent Prostate Cancer
- +3 more
- cryotherapy
- sargramostim
- Aurora, ColoradoUniversity of Colorado Cancer Center
2022-02-08
Feb 8, 2022Y
Completed
- Unspecified Adult Solid Tumor, Protocol Specific
- sargramostim
- topotecan hydrochloride
- New Haven, ConnecticutYale Comprehensive Cancer Center
2020-08-13
Aug 13, 2020U
Active, not recruiting
- HER2-positive Breast Cancer
- +8 more
- pNGVL3-hICD vaccine
- +6 more
- Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
2021-10-26
Oct 26, 2021N
Active, not recruiting
- Breast Ductal Carcinoma In Situ
- Laboratory Biomarker Analysis
- +3 more
- Boston, Massachusetts
- +3 more
2021-06-30
Jun 30, 2021L
Completed
- Transitional Cell Carcinoma
- TICE®-strain BCG
- +2 more
- New York, New YorkMemorial Sloan-Kettering Cancer Center
2021-07-08
Jul 8, 2021U
Recruiting
- Alzheimer Disease
- Sargramostim
- Saline - placebo comparator
- Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
2022-03-30
Mar 30, 2022N
Completed
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer AJCC v7
- Ipilimumab
- +3 more
- San Francisco, CaliforniaUCSF Medical Center-Mount Zion
2020-07-29
Jul 29, 2020J
Withdrawn
- Stage IB Melanoma
- +3 more
- sargramostim
- +3 more
- Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
2020-07-23
Jul 23, 2020M
Active, not recruiting
- Neuroblastoma (NB)
- Irinotecan
- +3 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-10-19
Oct 19, 2021N
Completed
- Lymphoma, Non-Hodgkin
- HIV Infections
- Bleomycin sulfate
- +8 more
- Los Angeles, CaliforniaUSC CRS
2021-10-26
Oct 26, 2021E
Recruiting
- Peripheral Artery Disease (PAD)
- GM-CSF
- Placebo
- Atlanta, GeorgiaEmory University Hospital
2021-10-08
Oct 8, 2021N
Not yet recruiting
- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- Natural Killer Cells
- +4 more
- (no location specified)
2022-01-11
Jan 11, 2022R
Completed
- Biliary Cancer
- Pembrolizumab
- Sargramostim
- San Francisco, CaliforniaUniversity of California San Francisco
2022-01-21
Jan 21, 2022N
Completed
- Sarcoma, Kaposi
- HIV Infections
- Interferon alfa-2b
- +2 more
- New York, New YorkMem Sloan - Kettering Cancer Ctr
2021-10-26
Oct 26, 2021